The FDA has initiated a pilot program to accelerate regulatory reviews of generic drugs that are tested and manufactured entirely in the United States using domestically sourced active ingredients. This effort forms part of a broader governmental strategy to reshore pharmaceutical production, aiming to enhance supply chain resilience and reduce dependency on foreign sources. Faster approval times are expected to benefit generic drug availability and competitive pricing.